

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

1-74. (canceled)

75. (Currently amended) A topical method of decreasing phagocytosis or ICAM-1 expression in a patient having one or more of the conditions consisting of pulmonary emphysema, immunological lung disorders, periodontal disease, atherosclerotic plaques, Mid-dermal elastosis, pigmentation disorders, psoriasis, eczema and Acne vulgaris, comprising applying topically to an affected organ of said patient a therapeutically phagocytosis- or ICAM-1 decreasing effective amount of composition containing active trypsin inhibitory activity comprising a non-denatured soy extract having active trypsin inhibitory activity in the amount of at least about 24%.

76. (Previously presented) The method of claim 75, wherein the composition inhibits the PAR-2 pathway.

77. (Previously presented) The method of claim 75, wherein the composition comprises a soybean extract comprising a serine protease inhibitor.

78. (Previously presented) The method of claim 77, wherein the soybean extract contains soybean trypsin inhibitor.

79. (Previously presented) The method of claim 75, wherein the affected organ contains PAR-2-expressing cells.

80. (Previously presented) The method of claim 79, wherein the affected organ contains cells selected from the group consisting of a keratinocyte, a fibroblast, and a professional phagocytic cell.

81. (Previously presented) The method of claim 80, wherein the affected organ

contains keratinocytes.

82. (Previously presented) The method of claim 80, wherein the affected organ contains fibroblasts.

83. (Previously presented) The method of claim 80, wherein the affected organ contains professional phagocytic cells.

84. (Previously presented) The method of claim 75, wherein the affected organ is a human organ.

85. (Canceled)